AzTrials
AzTrials

Lymphoma, Non-HodgkinPhase 2TAPURNCT02693535

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

A Phase 2 study testing Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT) in people with Lymphoma, Non-Hodgkin and Multiple Myeloma, run by American Society of Clinical Oncology at 181 sites in 2 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. Read more about this study

Who is it for?
Ages 12 years and older
What is being tested?
Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
4,200 participants
Where
181 sitesin 2 countries
Study dates
14 Mar 2016to 31 Dec 2028
Phase
Phase 2

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • 12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
  • Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).
  • Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
  • Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
  • Absolute neutrophil count ≥ 1500 µl
  • Hemoglobin ≥ 9.0 g/dl
Show all 17Show fewer
  • Platelets ≥ 75,000/µl
  • Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
  • Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
  • Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
  • Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).
  • Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
  • Ability to understand and the willingness to sign a written informed consent/assent document.
  • Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
  • For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
  • Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.
  • Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.

Who cannot join

  • Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
  • Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
  • Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
  • Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
  • Note: there are additional exclusion criteria that may apply

Trial locations and contacts

181 sites in 2 countries. Contact the study team or a site near you to ask about taking part.

Laurie Smith, MA contact

www.tapur.org

tapur@asco.org

181 sites in 2 countries

United States174 sites, 146 recruiting

  • The Queen's Medical Center - West Oahu

    ‘Ewa Beach, Hawaii, 96706

    Tim Kelleher, 8086918582, tkelleher@queens.org

    Jared Acoba, MD

    Recruiting

  • Lovelace Medical Center - Saint Joseph Square

    Albuquerque, New Mexico, 87102

    Leslie Byatt, (505) -925-0366, lpbyatt@salud.unm.edu

    Bernard Tawfik, MD

    Recruiting

  • Presbyterian Kaseman Hospital

    Albuquerque, New Mexico, 87110

    Monique Robertson, RN, (505)- 559-6100, mrobertso2@phs.org

    Bernard Tawfik, MD

    Recruiting

  • The University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico, 87131

    Sheri Westgate, RN-BSN, OCN, (505) -925-0383, swestgate@salud.unm.edu

    Bernard Tawfik, MD

    Recruiting

  • Lehigh Valley Hospital - Cedar Crest

    Allentown, Pennsylvania, 18103

    734-712-3671, MCRCwebsitecontactform@trinity-health.org

    Maged Khalil, MD

    Recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Altamonte Springs, Florida, 32701

    Active, not recruiting

  • Trinity Health Ann Arbor Hospital

    Ann Arbor, Michigan, 48106

    7347123671, MCRCwebsitecontactform@trinity-health.org

    Elie Dib, MD

    Recruiting

  • University of Michigan

    Ann Arbor, Michigan, 48109

    Active, not recruiting

  • Cancer Treatment Centers of America - Atlanta

    Atlanta, Georgia, 30265

    Elizabeth McKoy, RN, BSN, 770-400-7177, emckoy@coh.org

    Bamidele Adesunloye, MD

    Recruiting

  • Emory University Winship Cancer Institute

    Atlanta, Georgia, 30322

    Krystal Bagley, 404-778-8670, krystal.joi.bagley@emory.edu

    Olatunji Alese, MD

    Recruiting

  • Sutter Auburn

    Auburn, California, 95602

    Kirsten Babski, 916-878-4990, BabskiK@sutterhealth.org

    Nitin Rohatgi, MD

    Recruiting

  • Harold Alfond Center for Cancer Care

    Augusta, Maine, 04330

    Sandra Neptune, BSN, RN, 207-626-4811, sandra.neptune@mainegeneral.org

    Lindsay Hathaway, MD

    Recruiting

  • Jackson Laboratory - Maine Cancer Genomics Initiative

    Augusta, Maine, 04330

    Petra Helbig, CCRP, 207-664-4659, Petra.Helbig@jax.org

    Jens Rueter, MD

    Recruiting

  • University of Miami/Sylvester Cancer Institute - Aventura

    Aventura, Florida, 33180

    Carolina Troche, BS, 305-243-1481, cxt582@med.miami.edu

    Carmen Calfa, MD

    Recruiting

  • Waldo County General Hospital

    Belfast, Maine, 04915

    Jen - Dalton, MHA, BSN, RN, 2072948291, JDalton@mmc.org

    Roger Inhorn, MD

    Recruiting

  • Sutter Alta Bates

    Berkeley, California, 94705

    Christopher Tang, 510-204-3428, Christopher.Tang@sutterhealth.org

    Nitin Rohatgi, MD

    Recruiting

  • Lehigh Valley Hospital- Muhlenberg

    Bethlehem, Pennsylvania, 18017

    7347127251, MCRCwebsitecontactform@trinity-health.org

    Maged Khalil, MD

    Recruiting

  • SMHC Cancer Care and Blood Disorders -Biddeford

    Biddeford, Maine, 04005

    Jen - Dalton, 2072948291, JDalton@mmc.org

    Roger Inhorn, MD

    Recruiting

  • University of Alabama at Birmingham Comprehensive Cancer Center

    Birmingham, Alabama, 35294

    Kun Yuan, 205-644-2584, kunyuan@uabmc.edu

    Mehmet Akce, MD

    Recruiting

  • Sanford Health- Bismarck

    Bismarck, North Dakota, 58501

    Peter Kurniali, MD, 701-323-5741, peter.kurniali@sanfordhealth.org

    Peter Kurniali, MD

    Recruiting

  • SC Cancer Specialists at St. Joseph's/Candler Bluffton

    Bluffton, South Carolina, 29910

    Stephanie Smith, RN, MSN, OCN, 19128195723, smiths1@sjchs.org

    Mark Taylor, MD

    Recruiting

  • St. Joseph's/Candler Smith

    Bluffton, South Carolina, 29910

    Stephanie Smith, RN, MSN, OCN, 19128195723, smiths1@sjchs.org

    Mark Taylor, MD

    Recruiting

  • Summit Cancer Care at St. Josph's/Candler Bluffton

    Bluffton, South Carolina, 29910

    Stephanie Smith, RN, MSN, OCN, 19128195723, smiths1@sjchs.org

    Mark Taylor, MD

    Recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Bonita Springs, Florida, 34135

    Active, not recruiting

  • Northwest Medical Specialties

    Bonney Lake, Washington, 98391

    Jennifer Spokely, 253-999-3701, research@southsoundcare.org

    Frank Senecal, MD

    Recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Bradenton, Florida, 34211

    Active, not recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Brandon, Florida, 33511

    Active, not recruiting

  • Northern Light Cancer Care

    Brewer, Maine, 04412

    Carla Mancini, MHA, BSN, RN, 207-973-5581, cmancini@northernlight.org

    Sarah Sinclair, MD

    Recruiting

  • Raish Peavey Haskell Children's Cancer and Treatment Center

    Brewer, Maine, 04412

    Carla C Mancini, RN, BSN, OCN, 2079735581, cmancini@northernlight.org

    Sarah Sinclair, MD

    Recruiting

  • Saint Vincent's Medical Center (SVMC)

    Bridgeport, Connecticut, 06606

    860-972-4700, CancerResearchSupport@hhchealth.org

    Wylie Hosmer, MD

    Recruiting

  • MaineHealth Cancer Care -Brunswick

    Brunswick, Maine, 04011

    Jen - Dalton, MHA, BSN, RN, 2072948291, JDalton@mmc.org

    Roger Inhorn, MD

    Recruiting

  • Aurora Cancer Care - Burlington

    Burlington, Wisconsin, 53105

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Cape Coral, Florida, 33909

    Active, not recruiting

  • Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center

    Cedar City, Utah, 84720

    Jake Kolu, 435-705-1632, Jake.Kolu@imail.org

    Ramya Thota, MD

    Recruiting

  • Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina, 27599

    Emmie Cole, 919-966-4432, emmie_cole@med.unc.edu

    Shetal Patel, MD

    Recruiting

  • Atrium Health's Levine Cancer Institute

    Charlotte, North Carolina, 28277

    Jenna Gregory, MS, RN, Jenna.Gregory@atriumhealth.org

    Kathryn F. Mileham, MD, FACP

    Recruiting

  • Cancer Treatment Centers of America-Chicago

    Chicago, Illinois, 60099

    Office of Clinical Trials, 847-731-1777, CHIResearch@coh.org

    Evan Pisick, MD

    Recruiting

  • University of Cincinnati Medical Center

    Cincinnati, Ohio, 45219

    Kayla Webb, MSN, RN, 513-584-0599, webb2ka@ucmail.uc.edu

    Davendra Sohal, MD

    Recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Clearwater, Florida, 33761

    Active, not recruiting

  • NH Oncology - Hematology, PA

    Concord, New Hampshire, 03103

    Ali Fleury, 6033146888, A.Fleury@nhoh.com

    Michael Buff, MD

    Recruiting

  • University of Miami/Sylvester Cancer Institute - Lennar

    Coral Gables, Florida, 33146

    Carolina Troche, BS, 305-243-1481, cxt582@med.miami.edu

    Carmen Calfa, MD

    Recruiting

  • University of Miami/Sylvester Cancer Institute - Deerfield Beach

    Deerfield Beach, Florida, 33442

    Carolina Troche, BS, 305-243-1481, cxt582@med.miami.edu

    Carmen Calfa, MD

    Recruiting

  • Henry Ford Health Saint John Hospital

    Detroit, Michigan, 48236

    7347123671, MCRCwebsitecontactform@trinity-health.org

    Carrie Dul, MD

    Recruiting

  • Pocono Medical Center

    East Stroudsburg, Pennsylvania, 18301

    7347127251, MCRCwebsitecontactform@trinity-health.org

    Maged Khalil, MD

    Recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia, 22042

    Roxana Comfort, CRC, 571-472-0628, roxana.comfort@inova.org

    Timothy Cannon, MD

    Recruiting

  • Sanford Health- Fargo

    Fargo, North Dakota, 58122

    Anu Gaba, MD, 701-234-6161, anu.gaba@sanfordhealth.org

    Anu Gaba, MD

    Recruiting

  • Northwest Medical Specialties

    Federal Way, Washington, 98003

    Jennifer Spokely, 253-999-3701, research@southsoundcare.org

    Frank Senecal, MD

    Recruiting

  • Genesys Hurley Cancer Institute

    Flint, Michigan, 48503

    7347123671, MCRCwebsitecontactform@trinity-health.org

    Paul Adams, MD

    Recruiting

  • Holy Cross Hospital

    Fort Lauderdale, Florida, 33308

    7347123671, MCRCwebsitecontactform@trinity-health.org

    Zdenka Segota, MD

    Recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Fort Myers, Florida, 33901

    Active, not recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Fort Myers, Florida, 33905

    Active, not recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Fort Myers, Florida, 33908

    Active, not recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Gainesville, Florida, 32605

    Active, not recruiting

  • University of Florida Health

    Gainesville, Florida, 32610

    Anna Kukulka, RN, BSN, 352-293-2551, akukulka@ufl.edu

    Thomas George, MD

    Recruiting

  • Aurora Health Care - Germantown Health Center

    Germantown, Wisconsin, 53022

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Northwest Medical Specialties

    Gig Harbor, Washington, 98332

    Jennifer Spokely, 253-999-3701, research@southsoundcare.org

    Frank Senecal, MD

    Recruiting

  • Aurora Cancer Care - Grafton

    Grafton, Wisconsin, 53024

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Cancer Research Consortium of West Michigan

    Grand Rapids, Michigan, 49503

    Connie Szczepanek, RN, 616-391-1230, crcwm-regulatory@crcwm.org

    Kathleen J. Yost, MD

    Recruiting

  • Aurora BayCare Medical Center

    Green Bay, Wisconsin, 54311

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Hartford Hospital

    Hartford, Connecticut, 06102

    860-972-4700, CancerResearchSupport@hhchealth.org

    Wylie Hosmer, MD

    Recruiting

  • Lehigh Valley Hospital-Hazleton

    Hazleton, Pennsylvania, 18201

    7347127251, MCRCwebsitecontactform@trinity-health.org

    Maged Khalil, MD

    Recruiting

  • South Carolina Cancer Specialists

    Hilton Head Island, South Carolina, 29926

    Stephanie Smith, RN, MSN, OCN, 19128195723, smiths1@sjchs.org

    Mark Taylor, MD

    Recruiting

  • The Queen's Medical Center - POB I

    Honolulu, Hawaii, 96813

    Tim Kelleher, 8086918582, tkelleher@queens.org

    Jared Acoba, MD

    Recruiting

  • The Queen's Medical Center - Punchbowl

    Honolulu, Hawaii, 96813

    Tim Kelleher, 808 691-8582, tkelleher@queens.org

    Jared Acoba, MD

    Recruiting

  • The Queen's Medical Center - Kuakini

    Honolulu, Hawaii, 96817

    Tim Kelleher, 8086918582, tkelleher@queens.org

    Jared Acoba, MD

    Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030

    Kshipra Sharma, MPH, MS, 713-745-8431, Ksharma2@MDAnderson.org

    Funda Meric-Bernstam, MD

    Recruiting

  • Community Health Network (The University of Texas MD Anderson Cancer Center)

    Indianapolis, Indiana, 46250

    Kshipra Sharma, MPH, MS, 713-745-8431, Ksharma2@MDAnderson.org

    Funda Meric-Bernstam, MD

    Recruiting

  • New England Cancer Specialist

    Kennebunk, Maine, 04043

    Patricia C Collins, 2073033422, collip@newecs.org

    Christian Thomas, MD

    Recruiting

  • Aurora Cancer Care - Kenosha South

    Kenosha, Wisconsin, 53142

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Kettering Health

    Kettering, Ohio, 45429

    Allison Dymacek, BSN, RN, 937-395-8367, allison.dymacek@ketteringhealth.org

    Lex Leonhardt, DO

    Recruiting

  • York Hopsital Oncology & Infusion Care in Kittery

    Kittery, Maine, 03904

    Brenda i Kiberd, RN, 2073616115, Brenda.Kiberd@yorkhospital.com

    Marilyn McLaughlin, MD

    Recruiting

  • Northwell Health Monter Cancer Center

    Lake Success, New York, 11042

    Mary Agnes Templeton, 516-734-8979, mtempleton@northwell.edu

    Marina Frimer, MD

    Recruiting

  • University of Michigan Health - Sparrow Lansing

    Lansing, Michigan, 48912

    7347123671, MCRCwebsitecontactform@trinity-health.org

    Gordan Srkalovic, MD

    Recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Largo, Florida, 33770

    Active, not recruiting

  • Memorial Medical Center

    Las Cruces, New Mexico, 88011

    Kim Hoffman, RN, (575)- 556-6545, kim.hoffman@lpnt.net

    Bernard Tawfik, MD

    Recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Lecanto, Florida, 34461

    Active, not recruiting

  • Trinity Health Livonia Hospital

    Livonia, Michigan, 48154

    7347127251, MCRCwebsitecontactform@trinity-health.org

    Amit Mohindra, MD

    Recruiting

  • The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate

    Los Angeles, California, 90025

    Teri Mata, 310-231-2115, tmata@theangelesclinic.org

    Omid Hamid, MD

    Recruiting

  • Solinsky Center for Cancer Care

    Manchester, New Hampshire, 03103

    Ali Fleury, BA, CCRP, 603-314-6888, A.Fleury@nhoh.com

    Michael Buff, MD

    Recruiting

  • Aurora Bay Area Medical Center

    Marinette, Wisconsin, 54143

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Midstate Medical Center (MSMC)

    Meriden, Connecticut, 06451

    860-972-4700, CancerResearchSupport@hhchealth.org

    Wylie Hosmer, MD

    Recruiting

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136

    Carolina Troche, BS, 305-243-1481, cxt582@med.miami.edu

    Carmen Calfa, MD

    Recruiting

  • University of Miami/Sylvester Cancer Institute - Alex's Place

    Miami, Florida, 33136

    Carolina Troche, BS, 305-243-1481, cxt582@med.miami.edu

    Carmen Calfa, MD

    Recruiting

  • University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building

    Miami, Florida, 33136

    Carolina Troche, BS, 305-243-1481, cxt582@med.miami.edu

    Carmen Calfa, MD

    Recruiting

  • University of Miami/Sylvester Cancer Institute - Kendall

    Miami, Florida, 33176

    Carolina Troche, BS, 305-243-1481, cxt582@med.miami.edu

    Carmen Calfa, MD

    Recruiting

  • University of Miami/Sylvester Cancer Institute - Sole Mia

    Miami, Florida, 33181

    Carolina Troche, BS, 305-243-1481, cxt582@med.miami.edu

    Carmen Calfa, MD

    Recruiting

  • Aurora Cancer Care Milwaukee

    Milwaukee, Wisconsin, 53209

    Michelle M Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Aurora St. Luke's Medical Center

    Milwaukee, Wisconsin, 53215

    Michelle M Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Aurora Sinai Medical Center

    Milwaukee, Wisconsin, 53223

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Aurora West Allis Medical Center

    Milwaukee, Wisconsin, 53227

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Northern Westchester Hospital

    Mount Kisco, New York, 10549

    Jemima Jacob, MPH, 914-666-1366, jjacob22@northwell.edu

    Marina Frimer, MD

    Recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Naples, Florida, 34102

    Active, not recruiting

  • Tennessee Oncology - Nashville / Sarah Cannon Research Institute

    Nashville, Tennessee, 37203

    Ethan Trull, 615-329-7274, Ethan.Trull@SarahCannon.com

    Meredith McKean, MD, MPH

    Recruiting

  • The Hospital of Central Connecticut (HOCC) Cancer Center

    New Britain, Connecticut, 06053

    8609724700, CancerResearchSupport@hhchealth.org

    Wylie Hosmer, MD

    Recruiting

  • Cohen Children's Medical Center

    New Hyde Park, New York, 11040

    Shreya Seepersaud, 718-470-7146, sseepersaud2@northwell.edu

    Marina Frimer, MD

    Recruiting

  • Manhattan Eye, Ear, and Throat Hospital

    New York, New York, 10065

    Leila Nasr, lnasr@northwell.edu

    Marina Frimer, MD

    Recruiting

  • Staten Island University Hospital

    New York, New York, 10305

    Sammi Ruan, 718-226-1489, sruan2@northwell.edu

    Melissa McCarthy, 718-226-1805, mccarthy22@northwell.edu

    Recruiting

  • Stephens Memorial Hospital

    Norway, Maine, 04268

    Jen - Dalton, MHA, BSN, RN, 2072948291, JDalton@mmc.org

    Roger Inhorn, MD

    Recruiting

  • William W. Backus Hospital

    Norwich, Connecticut, 06360

    860-972-4700, CancerResearchSupport@hhchealth.org

    Wylie Hosmer, MD

    Recruiting

  • Kaiser Permanente - Oakland Medical Center

    Oakland, California, 94611

    Desiree Goldstein, desiree.goldstein@kp.org

    Jennifer M Suga, MD

    Recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Ocala, Florida, 34474

    Active, not recruiting

  • Northwest Medical Specialties

    Olympia, Washington, 98502

    Jennifer Spokely, 253-999-3701, research@southsoundcare.org

    Frank Senecal, MD

    Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

    Micki Bethea, BS, 402-559-8011, mbethea@unmc.edu

    Alissa Marr, MD

    Recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Orange City, Florida, 32763

    Active, not recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Orlando, Florida, 32806

    Active, not recruiting

  • Vince Lombardi Cancer Clinic - Oshkosh

    Oshkosh, Wisconsin, 54904

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Sutter Palo Alto Medical Foundation: Palo Alto

    Palo Alto, California, 94301

    clinicaltrials@pamf.org

    Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111

    Fathima S Sheriff, 215-728-4094, fathima.sheriff@fccc.edu

    Margaret von Mehren, MD

    Recruiting

  • Cancer Treatment Centers of America-Phoenix

    Phoenix, Arizona, 85338

    Alex Lizzul, 602-872-5654, alizzul@coh.org

    Sagun Shrestha, MD

    Recruiting

  • University of Miami/Sylvester Cancer Institute - Plantation

    Plantation, Florida, 33324

    Carolina Troche, BS, 305-243-1481, cxt582@med.miami.edu

    Carmen Calfa, MD

    Recruiting

  • Trinity Health Oakland Hospital

    Pontiac, Michigan, 48341

    7347123671, MCRCwebsitecontactform@trinity-health.org

    Julie Goodman, MD

    Recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Port Charlotte, Florida, 33980

    Active, not recruiting

  • Providence Health & Services

    Portland, Oregon, 97213

    Isa Ngirailemesang, 971-358-2056, Isa.Ngirailemesang@providence.org

    Evthokia Hobbs, MD

    Recruiting

  • New England Cancer Specialist

    Portsmouth, New Hampshire, 03801

    Patricia C Collins, BA, CCRC, 2073033422, collip@newecs.org

    Christian Thomas, MD

    Recruiting

  • Northwest Medical Specialties

    Puyallup, Washington, 98373

    Jennifer Spokely, 253-999-3701, reserch@southsoundcare.org

    Frank Senecal, MD

    Recruiting

  • Aurora Cancer Care - Racine

    Racine, Wisconsin, 53406

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Queens Cancer Center

    Rego Park, New York, 11374

    Harmandeep Kaur, 718-412-0773, hkaur37@northwell.edu

    Marina Frimer, MD

    Recruiting

  • Presbyterian Rust Medical Center

    Rio Rancho, New Mexico, 87124

    Andrea Yost, (505) -253-7878, ayost3@phs.org

    Bernard Tawfik, MD

    Recruiting

  • Penobscot Bay Medical Center

    Rockport, Maine, 04856

    Jen - Dalton, MHA, BSN, RN, 2072948291, JDalton@mmc.org

    Roger Inhorn, MD

    Recruiting

  • Kaiser Permanente - Roseville Medical Center

    Roseville, California, 95661

    Desiree Goldstein, desiree.goldstein@kp.org

    Jennifer M Suga, MD

    Recruiting

  • Sutter Roseville

    Roseville, California, 95661

    Kirsten Babski, 916-878-4990, BabskiK@sutterhealth.org

    Nitin Rohatgi, MD

    Recruiting

  • Kaiser Permanente - Sacramento Medical Center

    Sacramento, California, 95814

    Desiree Goldstein, desiree.goldstein@kp.org

    Jennifer M Suga, MD

    Recruiting

  • Sutter Sacramento

    Sacramento, California, 95816

    SIMR@sutterhealth.org

    Nitin Rohatgi, MD

    Recruiting

  • MyMichigan Medical Center Saginaw

    Saginaw, Michigan, 48601

    7347123671, MCRCwebsitecontactform@trinity-health.org

    Nicholas Damico, MD

    Recruiting

  • Intermountain Healthcare

    Salt Lake City, Utah, 84107

    Tracy Taylor, 801-507-3953, tracy.taylor@imail.org

    Ramya Thota, M.D.

    Recruiting

  • Kaiser Permanente - South San Francisco Medical Center

    San Francisco, California, 94080

    Desiree Goldstein, desiree.goldstein@kp.org

    Jennifer M Suga, MD

    Recruiting

  • California Pacific Medical Center Research Institute

    San Francisco, California, 94115

    415-600-1654, clinicalresearch@sutterhealth.org

    Nitin Rohatgi, MD

    Recruiting

  • Kaiser Permanente - San Francisco Medical Center

    San Francisco, California, 94115

    Desiree Goldstein, desiree.goldstein@kp.org

    Jennifer M Suga, MD

    Recruiting

  • Sutter Cancer Research Consortium

    San Francisco, California, 94115

    Laurel Brechtel, 415-600-1654, BrechtLa@cpmcri.org

    Stacy D'Andre, MD

    Recruiting

  • Kaiser Permanente - San Jose Medical Center

    San Jose, California, 95119

    Desiree Goldstein, desiree.goldstein@kp.org

    Jennifer M Suga, MD

    Recruiting

  • Kaiser Permanente - San Leandro Medical Center

    San Leandro, California, 94577

    Desiree Goldstein, desiree.goldstein@kp.org

    Jennifer M Suga, MD

    Recruiting

  • SMHC Cancer Care and Blood Disorders -Sandford

    Sanford, Maine, 04073

    Jen - Dalton, MHA, BSN, RN, 2072948291, JDalton@mmc.org

    Roger Inhorn, MD

    Recruiting

  • Sutter Sansum Clinic

    Santa Barbara, California, 93105

    Selina Perez, 831-458-5837, Selina.Perez@sutterhealth.org

    Nitin Rohatgi, MD

    Recruiting

  • Kaiser Permanente - Santa Clara Medical Center

    Santa Clara, California, 95051

    Desiree Goldstein, desiree.goldstein@kp.org

    Jennifer M Suga, MD

    Recruiting

  • Sutter Palo Alto Medical Foundation: Santa Cruz

    Santa Cruz, California, 95065

    clinicaltrials@pamf.org

    Recruiting

  • Sutter Palo Alto Medical Foundation: Fremont

    Santa Cruz, California, 994538

    clinicaltrials@pamf.org

    Recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Sarasota, Florida, 34236

    Active, not recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Sarasota, Florida, 34239

    Active, not recruiting

  • Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion

    Savannah, Georgia, 31405

    Stephanie Smith, RN, MSN, OCN, 9128195723, smiths1@sjchs.org

    Mark Taylor, MD

    Recruiting

  • Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute

    Savannah, Georgia, 31405

    Stephanie Smith, RN, MSN, OCN, 19128195723, smiths1@sjchs.org

    Mark Taylor, MD

    Recruiting

  • Lewis Cancer & Research Pavilion

    Savannah, Georgia, 31405

    Stephanie Smith, RN, MSN, OCN, 912-819-5723, smiths1@sjchs.org

    Mark Taylor, MD

    Recruiting

  • Summit Cancer Care

    Savannah, Georgia, 31405

    Stephanie Smith, RN, MSN, OCN, 9128195723, smiths1@sjchs.org

    Mark Taylor, MD

    Recruiting

  • Maine Children's Cancer Program

    Scarborough, Maine, 04074

    Jen - Dalton, MHA, BSN, RN, 2072948291, JDalton@mmc.org

    Roger Inhorn, MD

    Recruiting

  • Maine Medical Partner's Women's Health

    Scarborough, Maine, 04074

    Jen - Dalton, MHA, BSN, RN, 2072948291, JDalton@mmc.org

    Roger Inhorn, MD

    Recruiting

  • New England Cancer Specialist

    Scarborough, Maine, 04074

    Patricia Collins, BA, CCRC, 207-303-3422, collip@newecs.org

    Christian Thomas, MD

    Recruiting

  • Swedish Cancer Institute

    Seattle, Washington, 98104

    Sidney Ching, 206-386-3142, sidney.ching@swedish.org

    Philip Gold, MD

    Recruiting

  • Vince Lombardi Cancer Center

    Sheboygan, Wisconsin, 53081

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Sanford Cancer Center Oncology Clinic and Pharmacy

    Sioux Falls, South Dakota, 57104

    Steven Powell, MD, 605-328-8000, steven.powell@sanfordhealth.org

    Steven Powell, MD

    Recruiting

  • Phelps Hospital

    Sleepy Hollow, New York, 10591

    Barbara Turner, RN, 914-269-1949, Bturner1@northwell.edu

    Shyrley Gomez, Sgomez21@northwell.edu

    Recruiting

  • MaineHealth Cancer Care -South Portland

    South Portland, Maine, 04106

    Jen Dalton, MHA, BSN, RN, 207-294-8291, JDalton@mmc.org

    Roger Inhorn, MD

    Recruiting

  • Dixie Regional Medical Center-River Road Campus

    St. George, Utah, 84770

    Jake Kolu, 435-705-1632, Jake.Kolu@imail.org

    Ramya Thota, MD

    Recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    St. Petersburg, Florida, 33701

    Active, not recruiting

  • Aurora Medical Center in Summit

    Summit, Wisconsin, 53066

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Sutter Palo Alto Medical Foundation: Sunnyvale

    Sunnyvale, California, 94086

    clinicaltrials@pamf.org

    Recruiting

  • Northwest Medical Specialties

    Tacoma, Washington, 98405

    Jennifer Spokely, 253-999-3701, reserch@southsoundcare.org

    Frank Senecal, MD

    Recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Tampa, Florida, 33607

    Active, not recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Tavares, Florida, 32778

    Active, not recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    The Villages, Florida, 32159

    Active, not recruiting

  • New England Cancer Specialist

    Topsham, Maine, 04086

    Patricia C Collins, BA, CCRC, 12073033422, collip@newecs.org

    Christian Thomas, MD

    Recruiting

  • Charlotte Hungerford

    Torrington, Connecticut, 06790

    860-972-4700, CancerResearchSupport@hhchealth.org

    Wylie Hosmer, MD

    Recruiting

  • Michigan Cancer Research Consortium

    Traverse City, Michigan, 48341

    Beth LaVasseur, RN, MS, 734-712-7251, Beth.LaVasseur@stjoeshealth.org

    877-590-5995

    Recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Trinity, Florida, 34655

    Active, not recruiting

  • Vince Lombardi Cancer Clinic - Two Rivers

    Two Rivers, Wisconsin, 54241

    Michelle Toutloff, RN, CCRP, 9204567880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • Kaiser Permanente - Vallejo Medical Center

    Vallejo, California, 94589

    Desiree Goldstein, desiree.goldstein@kp.org

    Jennifer M. Suga, MD

    Recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Venice, Florida, 34285

    Active, not recruiting

  • Florida Cancer Specialists South / Sarah Cannon Research Institute

    Venice, Florida, 34292

    Active, not recruiting

  • Kaiser Permanente - Walnut Creek Medical Center

    Walnut Creek, California, 94596

    Desiree Goldstein, desiree.goldstein@kp.org

    Jennifer M Suga, MD

    Recruiting

  • Henry Ford Health Warren Hospital

    Warren, Michigan, 48093

    7347123671, MCRCwebsitecontactform@trinity-health.org

    Carrie Dul, MD

    Recruiting

  • Aurora Cancer Care - Milwaukee West

    Wauwatosa, Wisconsin, 53226

    Michelle Toutloff, RN, CCRP, 920-456-7880, Michelle.Martin2@aah.org

    Antony Ruggeri, MD

    Recruiting

  • York Hospital Oncology & Infusion Care in Wells

    Wells, Maine, 04090

    Brenda Kiberd, RN, 207-361-6115, Brenda.Kiberd@yorkhospital.com

    Marilyn McLaughlin, MD

    Recruiting

  • West Chester Hospital

    West Chester, Ohio, 45069

    Kayla Webb, MSN, RN, 513-584-0599, webb2ka@ucmail.uc.edu

    Trisha Wise-Draper, MD

    Recruiting

  • Windham Hospital (WH)

    Willimantic, Connecticut, 06226

    860-972-4700, CancerResearchSupport@hhchealth.org

    Wylie Hosmer, MD

    Recruiting

  • Florida Cancer Specialists North / Sarah Cannon Research Institute

    Winter Park, Florida, 32789

    Active, not recruiting

  • York Hospital Oncology & Infusion Care in York

    York Village, Maine, 03909

    Brenda i Kiberd, RN, 2073616115, Brenda.Kiberd@yorkhospital.com

    Marilyn McLaughlin, MD

    Recruiting

Other trials in United States

Puerto Rico7 sites, 7 recruiting

  • PanOncology Trials

    Cayey, Puerto Rico, 00737

    Natalia Ortiz, 787-407-3333, natalia.ortiz@panoncologytrials.com

    Maria Cruz Correa, MD

    Recruiting

  • PanOncology Trials

    Dorado, Puerto Rico, 00646

    Natalia Ortiz, 787-407-3333, natalia.ortiz@panoncologytrials.com

    Maria Cruz Correa, MD

    Recruiting

  • PanOncology Trials

    Manati, Puerto Rico, 00674

    Natalia Ortiz, 787-407-3333, natalia.ortiz@panoncologytrials.com

    Maria Crus Correa, MD

    Recruiting

  • PanOncology Trials

    Mayagüez, Puerto Rico, 00680

    Natalia Ortiz, 787-407-3333, natalia.ortiz@panoncologytrials.com

    Maria Cruz Correa, MD

    Recruiting

  • PanOncology Trials

    Ponce, Puerto Rico, 00730

    Natalia Ortiz, 787-407-3333, natalia.ortiz@panoncologytrials.com

    Maria Cruz Correa, MD

    Recruiting

  • PanOncology Trials

    San Juan, Puerto Rico, 00909

    Natalia Ortiz, 787-407-3333, natalia.ortiz@panoncologytrials.com

    Maria Cruz Correa, MD

    Recruiting

  • PanOncology Trials

    San Juan, Puerto Rico, 00935

    Natalia Ortiz, 787-407-3333, natalia.ortiz@panoncologytrials.com

    Maria Cruz Correa, MD

    Recruiting

Other trials in Puerto Rico

About this study

Official title: Targeted Agent and Profiling Utilization Registry (TAPUR) Study

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).

Read more

****************

Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.

****************

Read the detailed description

The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.

Being tested
Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
Keywords
cancer, off-label, precision medicine, targeted therapy
Medical subject headings
Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sunitinib (CLOSED TO ENROLLMENT)Drug

    Also called Sutent

    drug

  • Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)Drug

    Also called Herceptin and Perjeta

    drug

  • Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)Drug

    Also called Zelboraf and Cotellic

    drug

  • Olaparib (CLOSED TO ENROLLMENT)Drug

    Also called Lynparza

    drug

  • Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)Drug

    Also called Opdivo and Yervoy

    drug

  • Abemaciclib (CLOSED TO ENROLLMENT)Drug

    Also called Verzenio

    drug

  • Talazoparib (CLOSED TO ENROLLMENT)Drug

    Also called Talzenna

    drug

  • Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)Drug

    Also called Tecentriq and Talzenna

    drug

  • Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)Drug

    Also called Tukysa and Herceptin Hylecta

    drug

  • FutibatinibDrug

    Also called Lytgobi

    drug

  • Dabrafenib plus TrametinibDrug

    Also called tanfinlar, Mekinist

    Drug

  • Fam-Trastuzumab Deruxtecan-Nxki (TDxD)Drug

    Also called Enhertu

    Drug

Study groups in NCT02693535
Study groupRoleWhat they receive
Group 5 (CSF1R,PDGFR,VEGFR)OtherParticipants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations
Receives: Drug: Sunitinib (CLOSED TO ENROLLMENT)
Group 8 (ERBB2)OtherParticipants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
Receives: Drug: Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)
Group 9 (BRAF V600E/D/K/R)OtherParticipants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations
Receives: Drug: Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
Group 14 (BRCA1/2; ATM)OtherParticipants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions
Receives: Drug: Olaparib (CLOSED TO ENROLLMENT)
Group 16 (MSI-H, high mutational load and others)OtherParticipants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations
Receives: Drug: Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
Group 17 (CDKN2A, CDK4, CDK6)OtherParticipants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation
Receives: Drug: Abemaciclib (CLOSED TO ENROLLMENT)
Group 19 (BRCA1/2, PALB2)OtherParticipants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations
Receives: Drug: Talazoparib (CLOSED TO ENROLLMENT)
Group 21 (BRCA1/2, PALB2, ATM, and others)OtherParticipants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval
Receives: Drug: Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)
Group 24 (ERBB2)OtherParticipants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations
Receives: Drug: Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)
Group 25OtherParticipants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation
Receives: Drug: Futibatinib
Group 26 (BRAF V600 E mutation )OtherParticipants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation .
Receives: Drug: Dabrafenib plus Trametinib
Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)OtherParticipants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification)
Receives: Drug: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria

    Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used.

    Measured: Assessed at 16 weeks of treatment

Secondary outcomes (1)

  1. Overall survival (OS)

    OS will be estimated using the Kaplan-Meier method

    Measured: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Feb 2016 (estimated)
  2. Study start14 Mar 2016
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
4,200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02693535
Sponsor's protocol ID
Pro00014171
Acronym
TAPUR
Status last verified
Sep 2026
First submitted
11 Feb 2016
Last updated
22 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Diamond-Rossi SA, Rothe M, Garrett-Mayer E, Pisick E, Bleeker J, Ganti AK, Meric-Bernstam F, Moyers JT, Nair SG, Kadakia KC, Rohatgi N, Sahai V, Vijayvergia N, Gold PJ, Sharma MR, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study. JCO Precis Oncol. 2026 Oct;10(10):e2600703. doi: 10.1200/PO-26-00703. Epub 2026 Oct 16.

    PubMed 42886887

  • Srkalovic G, Rothe M, Garrett-Mayer E, Mileham KF, Adesunloye B, Pisick E, Leath CA 3rd, Colocci N, Chen MD, Meric-Bernstam F, Marr AS, Alese OB, Powell S, Rueter J, Benyounes A, Pontious C, Lewis MA, Thomas GW, Kier Y, Calfa CJ, von Mehren M, Acoba JD, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Oct;10(10):e2600454. doi: 10.1200/PO-26-00454. Epub 2026 Oct 7.

    PubMed 42842844

  • Veljovich DS, Rothe M, Garrett-Mayer E, Ali-Ahmad HM, Naumann RW, Siedel J, Chan JK, Gregory A, Pisick E, Adesunloye B, Arend RC, Bell M, Frimer M, Tawfik B, Thota R, Tsimberidou AM, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul;10(7):e2600456. doi: 10.1200/PO-26-00456. Epub 2026 Jul 15.

    PubMed 42456088

  • Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr;10(4):e2501205. doi: 10.1200/PO-25-01205. Epub 2026 Apr 30.

    PubMed 42060861

  • Pisick E, Rothe M, Garrett-Mayer E, Srkalovic G, Chan JK, Calfa CJ, Leath CA 3rd, Marr AS, Gold PJ, Crane EK, Moyers JT, Yost Butler K, Gaba A, Thota R, Harnden KK, Alese OB, Jain A, Rueter J, Gill S, George TJ, Frimer M, Kayali F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr;10(4):e2500985. doi: 10.1200/PO-25-00985. Epub 2026 Apr 22.

    PubMed 42018965

  • Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15.

    PubMed 41538762

  • Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16.

    PubMed 41100773

  • Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.

    PubMed 40610648

  • Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16.

    PubMed 39413339

  • Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219.

    PubMed 39013131

  • Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.

    PubMed 38865672

  • Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15.

    PubMed 38748939

  • Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615.

    PubMed 38564684

  • Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513.

    PubMed 38354330

  • Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.

    PubMed 38096472

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in